Skip to main content

REBLOZYL is for adults with very low- to intermediate-risk of myelodysplastic (MDS) who may need regular red blood cell (RBC) transfusions and who have never received an erythropoiesis-stimulating agent (ESA)

AND

REBLOZYL is also for adults with MDS-RS or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need RBC transfusions and have not responded well to or cannot receive an ESA.

 

Select (+) to find answers for some of the most commonly asked questions about the REBLOZYL experience

 

Is REBLOZYL right for me?

When choosing a medicine to help manage your MDS-related anemia, it’s important to be honest with your healthcare team. If you’re considering treatment, ask your healthcare team what’s possible when starting with REBLOZYL. Remember, you and your caregivers are your best advocates.

To help you remember topics to share with your healthcare team, have answers to questions 1-4 before your next visit and use questions 5-7 during your visit.

  1. My current and past anemia treatments, including red blood cell transfusions (if applicable):
  2. My current treatment goal(s):
    Examples of treatment goals could be to become transfusion independent or to raise hemoglobin levels.
  3. Anemia impacts these parts of my daily life:
  4. Symptoms I am currently experiencing:
    • Problems with memory or thinking
    • Pale or yellowish skin
    • Lightheadedness
    • Chills
    • Feeling tired
    • Headaches
    • Weakness
    • Shortness of breath
    • Dizziness
    • Muscle cramps and/or bone pains
  5. Could REBLOZYL be right for me? How is it different from other treatments?
  6. How might REBLOZYL help me achieve my treatment goals?
  7. What should I expect while on REBLOZYL? What are possible side effects?

 

 red blood cell (RBC) transfusions and who have never received an erythropoiesis-stimulating agent (ESA).

REBLOZYL adults with very low- to intermediate-risk  of REBLOZYL is for adults with very low- to intermediate-risk o

REBLOZYL is for adults with very low- to intermediate-risk MDS

 

REBLOZYL is used to treat anemia in adults with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

 

What should I know and expect when taking REBLOZYL?

 

When choosing a medicine to help manage your MDS-related anemia, it’s important to be honest with your healthcare team. If you’re considering treatment, ask your healthcare team what’s possible when starting with REBLOZYL. Remember, you and your caregivers are your best advocates.

To help you remember topics to share with your healthcare team, have answers to questions 1-4 before your next visit and use questions 5-7 during your visit.

  1. My current and past anemia treatments, including red blood cell transfusions (if applicable):
  2. My current treatment goal(s):
    Examples of treatment goals could be to become transfusion independent or to raise hemoglobin levels.
  3. Anemia impacts these parts of my daily life:
  4. Symptoms I am currently experiencing:
    • Problems with memory or thinking
    • Pale or yellowish skin
    • Lightheadedness
    • Chills
    • Feeling tired
    • Headaches
    • Weakness
    • Shortness of breath
    • Dizziness
    • Muscle cramps and/or bone pains
  5. Could REBLOZYL be right for me? How is it different from other treatments?
  6. How might REBLOZYL help me achieve my treatment goals?
  7. What should I expect while on REBLOZYL? What are possible side effects?

 

REBLOZYL is for adults with very low- to intermediate-risk of myelodysplastic (MDS) who may need regular red blood cell (RBC) transfusions and who have never received an erythropoiesis-stimulating agent (ESA).

AND

REBLOZYL is also for adults with MDS-RS or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need RBC transfusions and have not responded well to or cannot receive an ESA.

 

REBLOZYL is used to treat anemia in adults with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.



swoosh

This website is intended for U.S. residents 18 years of age or older.

REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.
Access Support® and Your REBLOZYL Connection are trademarks of Bristol-Myers Squibb Company.
REBLOZYL® is licensed from Merck & Co., Inc., Rahway, NJ, USA and its affiliates.

© 2025 Bristol-Myers Squibb Company.

2007-US-2500423     12/25